Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs.

Charbonneau M, Gagnon MA.

Health Policy. 2018 Dec;122(12):1295-1301. doi: 10.1016/j.healthpol.2018.08.006. Epub 2018 Aug 25.

PMID:
30241797
2.

Combating corruption in the pharmaceutical arena.

Lexchin J, Kohler JC, Gagnon MA, Crombie J, Thacker P, Shnier A.

Indian J Med Ethics. 2018 Jul-Sep;3(3):234-239. doi: 10.20529/IJME.2018.022. Epub 2018 Mar 15.

3.

Evaluating the effects of Quebec's private-public drug insurance system.

Morgan SG, Gagnon MA, Charbonneau M, Vadeboncoeur A.

CMAJ. 2017 Oct 10;189(40):E1259-E1263. doi: 10.1503/cmaj.170726. Review. No abstract available.

4.

Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.

Gagnon MA, Volesky KD.

Global Health. 2017 Aug 22;13(1):62. doi: 10.1186/s12992-017-0285-x.

5.

The role and impact of cost-sharing mechanisms for prescription drug coverage.

Gagnon MA.

CMAJ. 2017 May 15;189(19):E680-E681. doi: 10.1503/cmaj.170169. No abstract available.

6.

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.

Morgan SG, Gagnon MA, Mintzes B, Lexchin J.

Healthc Policy. 2016 Aug;12(1):18-36.

7.

New drug pricing: does it make any sense?

Gagnon MA.

Prescrire Int. 2015 Jul;24(162):192-5. No abstract available.

PMID:
26237844
8.

[Three types of brand name loyalty strategies set up by drug manufacturers].

PréMont MC, Gagnon MA.

Healthc Policy. 2014 Nov;10(2):79-89. French.

9.

Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings.

O'Brady S, Gagnon MA, Cassels A.

Health Policy. 2015 Feb;119(2):224-31. doi: 10.1016/j.healthpol.2014.11.013. Epub 2014 Nov 22.

10.
11.

Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health.

Gagnon MA.

J Law Med Ethics. 2013 Fall;41(3):571-80. doi: 10.1111/jlme.12066.

PMID:
24088147
12.

Drug shortages: searching for a cure.

Gagnon MA.

Healthc Policy. 2012 May;7(4):10-7.

13.

Comparison of the structure and the transport properties of low-set and high-set curdlan hydrogels.

Gagnon MA, Lafleur M.

J Colloid Interface Sci. 2011 May 15;357(2):419-27. doi: 10.1016/j.jcis.2011.02.033. Epub 2011 Feb 17.

PMID:
21402382
14.

Comparison between nuclear magnetic resonance profiling and the source/sink approach for characterizing drug diffusion in hydrogel matrices.

Gagnon MA, Lafleur M.

Pharm Dev Technol. 2011 Nov-Dec;16(6):651-6. doi: 10.3109/10837450.2010.502900. Epub 2010 Aug 5.

PMID:
20687774
15.

Self-diffusion and mutual diffusion of small molecules in high-set curdlan hydrogels studied by 31P NMR.

Gagnon MA, Lafleur M.

J Phys Chem B. 2009 Jul 9;113(27):9084-91. doi: 10.1021/jp811105p.

PMID:
19522479
16.

The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.

Gagnon MA, Lexchin J.

PLoS Med. 2008 Jan 3;5(1):e1. doi: 10.1371/journal.pmed.0050001. No abstract available.

17.

Role of the ammonium group in the diffusion of quaternary ammonium compounds in Streptococcus mutans biofilms.

Sandt C, Barbeau J, Gagnon MA, Lafleur M.

J Antimicrob Chemother. 2007 Dec;60(6):1281-7. Epub 2007 Oct 10.

PMID:
17932074
18.

Supplemental Content

Loading ...
Support Center